Cargando…
What is the next generation therapeutic strategy for castration-resistant prostate cancer
Prostate cancer (PCa) is one of the most common cancers in the world. Since androgen receptor (AR) signal plays key roles in the PCa progression, targeting androgens via the current androgen deprivation therapy (ADT) is the main therapeutic strategy for advanced PCa. However, most patients who recei...
Autores principales: | Wen, Si-Meng, Quan, Chang-Yi, Jiang, Ning, Shang, Zhi-Qun, Niu, Yuan-Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650465/ https://www.ncbi.nlm.nih.gov/pubmed/25432503 http://dx.doi.org/10.4103/1008-682X.143311 |
Ejemplares similares
-
Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014) -
Next generation patient-derived prostate cancer xenograft models
por: Lin, Dong, et al.
Publicado: (2014) -
More evidence intratumoral DHT synthesis drives castration-resistant prostate cancer
por: Wilson, Elizabeth M
Publicado: (2014) -
Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all
por: Maughan, Benjamin L, et al.
Publicado: (2014) -
Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2015)